Literature DB >> 8686102

Antineutrophil cytoplasmic antibodies in myelodysplasia.

D R Hull1, S A McMillan, I M Rea, N Boyd, M F McMullin.   

Abstract

Antibodies to neutrophil cytoplasmic antigens (ANCA) are good serological markers for patients with mainly vasculitic conditions. Two main types of ANCAs have been detected, the first termed cytoplasmic antineutrophil cytoplasmic antibody (cANCA) are mainly associated with patients with Wegener's granulomatosis, the other termed perinuclear antineutrophil cytoplasmic antibody (pANCA) are mainly associated with patients with renal vasculitis, rheumatic and collagen disorders. These antibodies are against various constituents of neutrophil granules. In patients with myelodysplasia, defects in normal granulocyte development are seen. We report a series of twelve patients with myelodysplasia of whom at least four showed a low titre and one a high titre of pANCA. Two of these patients also had demonstrable activity against myeloperoxidase (MPO). None of these patients had any evidence of systemic or cutaneous vasculitis or of any autoimmune disorder. There was no pANCA positivity in an age matched control group.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8686102      PMCID: PMC2448746     

Source DB:  PubMed          Journal:  Ulster Med J        ISSN: 0041-6193


  10 in total

1.  Systemic vasculitis and myelodysplasia.

Authors:  A J Warren; U M Hegde; A Nathwani; I A Reilly
Journal:  Br J Haematol       Date:  1990-08       Impact factor: 6.998

2.  Cutaneous vasculitis in patients with myelodysplasia.

Authors:  A R Green; D Shuttleworth; D T Bowen; D P Bentley
Journal:  Br J Haematol       Date:  1990-03       Impact factor: 6.998

3.  Delineation of a standard procedure for indirect immunofluorescence detection of ANCA.

Authors:  A Wiik
Journal:  APMIS Suppl       Date:  1989

Review 4.  ANCA: a class of vasculitis-associated autoantibodies against myeloid granule proteins: clinical and laboratory aspects and possible pathogenetic implications.

Authors:  R Goldschmeding; J W Tervaert; K M Dolman; A E von dem Borne; C G Kallenberg
Journal:  Adv Exp Med Biol       Date:  1991       Impact factor: 2.622

Review 5.  Granulocyte function in myelodysplastic syndromes.

Authors:  P Ruutu
Journal:  Scand J Haematol Suppl       Date:  1986

Review 6.  Antineutrophil cytoplasmic autoantibodies: a review of the antigens involved, the assays, and the clinical and possible pathogenetic consequences.

Authors:  E C Hagen; B E Ballieux; L A van Es; M R Daha; F J van der Woude
Journal:  Blood       Date:  1993-04-15       Impact factor: 22.113

7.  Proposals for the classification of the myelodysplastic syndromes.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1982-06       Impact factor: 6.998

Review 8.  ANCA and associated diseases: immunodiagnostic and pathogenetic aspects.

Authors:  W L Gross; W H Schmitt; E Csernok
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

9.  Blood neutrophil function in primary myelodysplastic syndromes.

Authors:  M A Boogaerts; V Nelissen; C Roelant; W Goossens
Journal:  Br J Haematol       Date:  1983-10       Impact factor: 6.998

10.  Bone marrow culture studies in refractory cytopenia and 'smouldering leukaemia'.

Authors:  G R Milner; N G Testa; C G Geary; T M Dexter; S Muldal; J E MacIver; L G Lajtha
Journal:  Br J Haematol       Date:  1977-02       Impact factor: 6.998

  10 in total
  3 in total

Review 1.  Churg-Strauss syndrome.

Authors:  M Conron; H L Beynon
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

2.  Prevalence of antineutrophil cytoplasmic antibody positivity in patients with Hodgkin's and non-Hodgkin lymphoma: a single center experience.

Authors:  Timucin Cil; Abdullah Altintas; Abdurrahman Isikdogan; Sabri Batun
Journal:  Int J Hematol       Date:  2009-05-27       Impact factor: 2.490

3.  Antiretroviral activity of 5-azacytidine during treatment of a HTLV-1 positive myelodysplastic syndrome with autoimmune manifestations.

Authors:  Panagiotis T Diamantopoulos; Maria Michael; Olga Benopoulou; Efthymia Bazanis; George Tzeletas; John Meletis; George Vayopoulos; Nora-Athina Viniou
Journal:  Virol J       Date:  2012-01-03       Impact factor: 4.099

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.